Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Puts A Halt To Drug Price Increases While Awaiting More On Trump's Blueprint

Executive Summary

Novartis joined Pfizer in agreeing to hold off on any further US drug price increases this year, saying the decision was prudent in the current environment. On Trump's drug pricing blueprint, Novartis said it is carefully monitoring how policy evolves this year before charting a course for 2019.

You may also be interested in...



US Drug Pricing Challenges Poised To Impact Pharma Growth, Leerink Warns

Drug price increases have contributed significantly to US revenue growth, about 61% for the 45 largest pharmaceutical products sold over the last three years, according to an analysis by Leerink. Investors should brace for declining growth rates for certain products that generate the bulk of their sales in the US, analyst Geoffrey Porges warned.

Merck's New Pricing Pledge Shows Style Over Substance

A 60% price reduction on hepatitis C drug Zepatier sounds impressive, but the drug has been declining and the HCV space overall is shrinking. Another set of 10% reductions come on small-sellers that are now generic. 

As J&J Sees Continued Drug Price Declines, CEO Urges Slow Policy Change Via Trump's Blueprint

J&J told investors to anticipate negative net drug pricing of 4%-6% across its portfolio in 2018, following a 4.6% negative impact in 2017. CEO Alex Gorsky also cautioned against changing drug pricing policy too quickly.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel